scispace - formally typeset
L

Li Zhang

Researcher at Binzhou University

Publications -  42
Citations -  3421

Li Zhang is an academic researcher from Binzhou University. The author has contributed to research in topics: Cervical loop & Ameloblast. The author has an hindex of 16, co-authored 36 publications receiving 1743 citations. Previous affiliations of Li Zhang include China Food and Drug Administration & Wuhan University.

Papers
More filters
Journal ArticleDOI

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity.

TL;DR: Most variants with amino acid change at receptor binding domain were less infectious but variants including A475V, L452R, V483A and F490L became resistant to some neutralizing antibodies, while deletion of both N331 and N343 glycosylation drastically reduced infectivity, revealing the importance of gly cosylation for viral infectivity.
Journal ArticleDOI

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.

TL;DR: A robust pseudovirus-based neutralization assay for SARS-CoV-2 is established and is glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.
Journal ArticleDOI

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape.

TL;DR: In this article, experiments with 18 pseudotyped viruses showed that the 501Y.V2 variants do not confer increased infectivity in multiple cell types except for murine ACE2-overexpressing cells, where a substantial increase in infectivity was observed.
Journal ArticleDOI

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development.

TL;DR: In this article, the crucial role of cathepsin L (CTSL) in patients with COVID-19 infection was reported and the circulating level of CTSL was elevated after SARS-CoV-2 infection and was positively correlated with disease course and severity.
Journal ArticleDOI

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

TL;DR: A pseudotyped virus-based neutralization assay against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in biosafety level 2 facilities to assess the level of neutralizing antibodies or molecular inhibitors in a sample.